Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Adverse effects on women: faecal incontinence during first 10 postpartum days · postpartum women who underwent surgical repair of third degree perineal tears
It is very uncertain whether laxative plus bulking agent changes adverse effects on women: faecal incontinence during first 10… compared with laxative alone (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects in the short term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: doctors' assessment of adverse effects UKU (events)… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ presurgical · participants with recurrent herpes labialis
Interferon probably leads to higher adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis
1 finding from 1 review
Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks) · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in common adverse effects ‐ Photosensitivity (Time point of… compared with PUVA alone (low certainty).
1 finding from 1 review
Adverse effect: clinically important adverse effect of intervention ‐ as defined by individual studies · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis
Topical foscarnet showed no clear difference in adverse effects during use of the preventative intervention (leading… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ application site reaction · participants with recurrent herpes labialis
Topical foscarnet showed no clear difference in adverse effects during use of the preventative intervention… compared with placebo (moderate certainty).
1 finding from 1 review